AngioDynamics, Inc. (ANGO) News
Filter ANGO News Items
ANGO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ANGO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ANGO News From Around the Web
Below are the latest news stories about ANGIODYNAMICS INC that investors may wish to consider to help them evaluate ANGO as an investment opportunity.
AngioDynamics Stock Up on Q2 Earnings Beat, Gross Margin DeclinesANGO registers overall strong top-line results on a pro-forma basis in second-quarter fiscal 2025, driven by strength in the Med Tech business. |
AngioDynamics Reports Growth and Advances NanoKnife SystemAn announcement from AngioDynamics ( (ANGO) ) is now available. AngioDynamics reported its fiscal year 2025 second-quarter financial results, highlighting a 9.2% increase in net sales driven by strong performance in its Med Tech segment, which grew by 25%. The company achieved key milestones for its NanoKnife System, receiving CPT Category I Codes and FDA 510(k) clearance for prostate tissue ablation, positioning it for accelerated growth. Despite a GAAP net loss, AngioDynamics showed improved a |
AngioDynamics Inc (ANGO) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...AngioDynamics Inc (ANGO) reports a robust 9% revenue growth, driven by MedTech and mechanical thrombectomy segments, while navigating manufacturing transitions. |
Q2 2025 AngioDynamics Inc Earnings CallQ2 2025 AngioDynamics Inc Earnings Call |
AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call TranscriptAngioDynamics, Inc. (ANGO) Q2 2025 Earnings Conference Call January 08, 2025, 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Stephen Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants John Young - Canaccord Genuity Steven Lichtman - Oppenheimer Yi Chen - H.C. Wainwright Presentation Operator Good morning and welcome to the AngioDynamics Fiscal Year 2025 Second Quarter Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being... |
AngioDynamics (ANGO) Reports Q2 Loss, Tops Revenue EstimatesAngioDynamics (ANGO) delivered earnings and revenue surprises of 63.64% and 2.36%, respectively, for the quarter ended November 2024. Do the numbers hold clues to what lies ahead for the stock? |
AngioDynamics: Fiscal Q2 Earnings SnapshotLATHAM, N.Y. (AP) — AngioDynamics Inc. ANGO) on Wednesday reported a loss of $10.7 million in its fiscal second quarter. On a per-share basis, the Latham, New York-based company said it had a loss of 26 cents. |
AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial ResultsLATHAM, N.Y., January 08, 2025--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2025, which ended November 30, 2024. |
AngioDynamics to Present at the J.P. Morgan Healthcare ConferenceLATHAM, N.Y., January 06, 2025--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference at 7:30 |
AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ SystemLATHAM, N.Y., January 06, 2025--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that the Company will host a virtual investor event on Wednesday, January 8, 2025 at 9:30am ET. This event will take place following the previously announced Fiscal 2025 Second Quarter Financial Results Confer |